MRS 2578

MRS 2578 is a selective and potent P2Y6 receptor antagonist with IC50s of 37 nM (human) and 98 nM (rat) . MRS 2578 exhibits insignificant activity at P2Y1, P2Y2, P2Y4, and P2Y11 receptors[1][2].

Product Specifications

CAS Number

[711019-86-2]

UNSPSC

12352005

Hazard Statement

H301, H334

Target

Apoptosis; P2Y Receptor

Type

Reference compound

Related Pathways

Apoptosis; GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/MRS-2578.html

Purity

98.15

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

S=C(NCCCCNC(NC1=CC(N=C=S)=CC=C1)=S)NC2=CC(N=C=S)=CC=C2

Molecular Formula

C20H20N6S4

Molecular Weight

472.67

Precautions

H301, H334

References & Citations

[1]Mamedova LK, et al. Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol, 2004, 67 (9), 1763-1770.|[2]Riegel AK, et al. Selective induction of endothelial P2Y6 nucleotide receptor promotes vascular inflammation. Blood, 2011, 117 (8), 2548-2555.|[3]Vieira RP, et al. Purinergic receptor type 6 contributes to airway inflammation and remodeling in experimental allergic airway inflammation. Am J Respir Crit Care Med, 2011, 184 (2), 215-223.|[4]Nishida M, et al. P2Y6 receptor-Galpha12/13 signalling in cardiomyocytes triggers pressure overload-induced cardiacfibrosis. EMBO J. 2008 Dec 3;27 (23) :3104-15.